Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
1 clinical trials · Condition
◉ Watch Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
| Record | Firm | Date |
|---|---|---|
| Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors (NCT05901285) | Vaxiion Therapeutics | 2023-11-02 |
Track Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab automatically
Every clearance here is in the API, with alerts when new ones post.